Key result
Sacubitril/valsartan is superior to target doses of an ACE inhibitor in reducing cardiovascular death and disease progression in patients with chronic heart failure and reduced ejection fraction.
Why the study?
Does sacubitril/valsartan reduce cardiovascular death and clinical disease progression compared to ACE inhibitors in patients with chronic heart failure and reduced EF?
Does sacubitril/valsartan reduce cardiovascular death and clinical disease progression compared to ACE inhibitors in patients with chronic heart failure and reduced EF?
This review addresses misconceptions about the PARADIGM-HF trial and supports the guideline recommendation of sacubitril/valsartan as the preferred renin-angiotensin system inhibitor for HFrEF.
No takes yet. Share an insight, caveat, or question.
Supports HFrEF guideline preference for sacubitril/valsartan; leaves open broader real-world validation needs.
Milton Packer (2016) conducted a review in chronic heart failure with reduced ejection fraction. sacubitril/valsartan vs. target doses of an ACE inhibitor was evaluated on cardiovascular death and clinical disease progression. Sacubitril/valsartan is superior to target doses of an ACE inhibitor in reducing cardiovascular death and disease progression in patients with chronic heart failure and reduced ejection fraction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: